FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum
ERIS Share Price Target
Eris Lifesciences Ltd.
Sector: Pharmaceuticals and health care
Sector: Pharmaceuticals and health care
ERIS Long Term Analysts Rating
- ★★
- ★★
- ★★
- ★★
- ★★
4/5 (4 Ratings)
ERIS Share Price *
507 +3.4 (0.68%)
* (quote may be delayed)
4 ERIS share price target reports by brokerages below. See what is analyst's view on ERIS share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
You can also find ERIS share price target tomorrow or next week from ERIS discussion forum.
ERIS Share Price Forecast - Consensus
| No. of reports in last year | 4 |
| No. of analysts | 1 |
| Average Consensus Forecast | 518.00 |
| Consensus Potential | -0.40% |
ERIS Share Price Target - Broker Reports - 2019
Prabhudas Lilladher
21-Nov-19
Price @ Call: 415.24
Target: 459
ACCUMULATE
We met the management of ERIS and came out confident on its growth plans. Eris plans to change its gear from defensive approach (In FY18 and 19) in India formulations with plans to expand franchisee of current portfolio, launches off-patent molecules, foray in new therapeutic areas, acquisitions of brands, in-licensing molecules and additions of new headcounts. With CNS portfolio return to growth path along with aggressive launches and superior MR productivity, our revenue assumptions discounted visible growth levers and discount in earnings growth 15% CAGR in FY19-21E. We maintain our recommendation ‘Accumulate’ and retain TP Rs459.
Prabhudas Lilladher
7-Nov-19
Price @ Call: 422.67
Target: 459
ACCUMULATE
With 58% contribution of Guwahati plant in revenues, ERIS guided for more capacity utilisation including producitons of Strides portfolio. This helps for better tax management with guidance of 8-10% in FY20E. Guwahati remains to be tax benefit zone till FY24E. With better traction of new products/brands, incremental Rx and net cash position, we expect stronger cash flows and higher return ratios. With stability of sales from the acquired portfolios and better visibility of earnings, we maintain ‘Accumulate’ and retain TP at Rs459 We maintian ‘Accumulate’ recommendation.
Prabhudas Lilladher
29-Jul-19
Price @ Call: 400.6
Target: 459
ACCUMULATE
We expect sales at 16% CAGR in FY19-21E while management guided 30-50% more than the average growth of IPM and EBITDA to be rangebound, alluding to be around 34-37%. With Guwahati plant contribution in operating revenues at 61%, the management guided for more capacity utilisation to manufacture more products from Strides portfolio. This helps for better tax management with guidance of 8-10% in FY20E. Guwahati remains to be tax benefit zone till FY24E. With better traction of new products/brands, incremental Rx and net cash position, we expect stronger cash flows and higher return ratios. With stability of sales from the acquired portfolios and better visibility of earnings, we maintain ‘Accumulate’ and retain TP at Rs459 on PE 16x of FY21Eearnigns. We maintian ‘Accumulate’.
Prabhudas Lilladher
30-Jan-19
Price @ Call: 669.2
Target: 695
ACCUMULATE
ERIS Share Price Target - Broker Reports - 2018
Prabhudas Lilladher
6-Nov-18
Price @ Call: 652.48
Target: 704
ACCUMULATE
AnandRathi
22-Oct-18
Price @ Call: 708.4
Target: 879
BUY
Prabhudas Lilladher
28-May-18
Price @ Call: 774.82
Target: 885
ACCUMULATE
Prabhudas Lilladher
8-May-18
Price @ Call: 750.1
Target: 885
ACCUMULATE
Ventura
12-Apr-18
Price @ Call: 802.9
Target: 1060
BUY
ERIS Share Price Target - Broker Reports - 2017
Axis Direct
27-Nov-17
Price @ Call: 648.24
Target: 800
BUY
Bonanza
30-Oct-17
Price @ Call: 570
Target: 686
BUY
Axis Direct
21-Aug-17
Price @ Call: 590
Target: 730
BUY
- keyboard_arrow_down
ERIS Peer Stocks - Share Price Targets
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.